Roche Holding AG (RHHBY)
| Market Cap | 366.13B +44.0% |
| Revenue (ttm) | 77.92B -0.8% |
| Net Income | 15.27B +30.9% |
| EPS | 18.98 +30.6% |
| Shares Out | n/a |
| PE Ratio | 23.97 |
| Forward PE | 17.35 |
| Dividend | 0.97 (1.78%) |
| Ex-Dividend Date | Mar 13, 2026 |
| Volume | 324,337 |
| Open | 56.50 |
| Previous Close | 55.52 |
| Day's Range | 56.49 - 58.41 |
| 52-Week Range | 39.50 - 60.85 |
| Beta | 0.35 |
| Analysts | Buy |
| Price Target | 59.66 (+2.44%) |
| Earnings Date | Jul 23, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial numbers in CHF Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for RHHBY stock is "Buy." The 12-month stock price target is $59.66, which is an increase of 2.44% from the latest price.
News
IDEAYA Biosciences Signs Clinical Collaboration With Genentech On Pancreatic Cancer Study
(RTTNews) - Wednesday, IDEAYA Biosciences, Inc. (IDYA) announced a clinical collaboration with Genentech, a member of the Roche Group, to evaluate the efficacy and safety of IDE892 in combination with...
Genentech Marks Topping out Milestone for New Holly Springs, North Carolina Manufacturing Facility
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), today raised the final beam of its new manufacturing facility in Holly Spr...
Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updates
Recursion Pharmaceuticals NASDAQ: RXRX is using artificial intelligence to generate and analyze biological data in an effort to improve drug discovery, advance internal therapeutic programs and suppor...
RHHBY Looks 36.1% Overvalued on GF Value⢠Amid Dividend Sustainability Concerns
RHHBY Looks 36.1% Overvalued on GF Value⢠Amid Dividend Sustainability Concerns
Drugmakers curb Swiss reimbursement applications over US pricing concerns
Drugmakers are holding back applications for health insurance coverage in Switzerland over concerns that lower prices there could affect their U.S. business under drug-pricing policies introduced by ...
Recursion (RXRX) Q2 2026 Earnings Call Transcript
AI-native drug discovery advances neuroscience target with Roche while cutting cash guidance.
Roche celebrate Division 2 title as Mitchels send Plunketts down
Louth GAA Division 2
Roche Stock Jumps as Morgan Stanley Sees Drug Breakout
Roche Stock Jumps as Morgan Stanley Sees Drug Breakout
RHHBY Looks 39.5% Overvalued on GF Valueâ¢
RHHBY Looks 39.5% Overvalued on GF Valueâ¢
Roche upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley upgraded Roche (RHHBY) to Overweight from Equal Weight with a price target of $63, up from $46. The firm says the company offers a “strong mix of visible…
Roche launches two new cyclospora tests as US outbreak widens
Roche said on Thursday it launched two new tests to detect cyclospora, as U.S. cyclosporiasis cases climbed to record levels this year making the foodborne-illness outbreak one of the largest in the...
Roche expands cyclospora testing portfolio to support U.S. public health response
Roche has launched two new, real-time PCR tests to detect cyclospora, a diarrhea-causing infection, to help meet diverse needs of laboratories. The new tests expand the Roche cyclospora portfolio, pro...
Labcorp launches FDA-approved PTEN companion diagnostic for prostate cancer
Labcorp (LH) announced the nationwide availability of Roche’s (RHHBY) VENTANA PTEN (SP218) RxDx Assay, the first immunohistochemistry companion diagnostic test approved by the U.S. FDA to determine PT...
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer
PARIS--(BUSINESS WIRE)--Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, ...
Genprex announces collaboration with Roche Diagnostics
Genprex (GNPX) announced its collaboration with Roche Diagnostics (RHHBY) to validate biomarkers for patient selection in clinical trials for non-small cell lung cancer. Building on promising preclini...
Roche sues Biocon over proposed breast-cancer drug copy
Roche's Genentech has sued Indian biopharmaceutical company Biocon in New Jersey federal court, alleging its proposed biosimilar of Genentech's blockbuster breast-cancer drug Perjeta would infringe Ge...
Swiss Market Index Rises as US-Iran Pause Lifts Sentiment, Defensive Pharma Giants Anchor Gains Monday
The Swiss Market Index rose as U.S.-Iran tensions eased, boosting European markets and lowering oil prices. Defensive stocks like Roche and Novartis led the gains amid ongoing geopolitical uncertainti...
How Roche Unexpectedly Buoyed IBD Stock Of The Day TG Therapeutics
TG Therapeutics is Friday's IBD Stock Of The Day after shares rebounded into a profit-taking zone on key comments from chief rival Roche.
Roche Receives FDA Clearance For Cobas BV/CV Assay To Improve Vaginitis Diagnosis
(RTTNews) - Roche (RHHBY) announced that the U.S. FDA has granted 510(k) clearance for its cobas BV/CV assay, a molecular diagnostic test designed to simultaneously detect Bacterial vaginosis (BV) and...
Roche Holding's Vaginitis Diagnostic Test Secures FDA 510(k) Clearance
(RTTNews) - Friday, Roche Holding AG (RHHBY.PK) announced that the U.S. Food and Drug Administration has granted 510(k) clearance to its cobas Bacterial vaginosis/Candida vaginitis or BV/CV assay for ...
Roche announces EMA’s CHMP recommended approval of Susvimo
Roche (RHHBY) announced that the European Medicines Agency’s, EMA, Committee for Medicinal Products for Human Use, CHMP, has recommended the approval of Susvimo 100 mg/mL for the treatment of neovascu...
Roche receives FDA 510(k) clearance for cobas BV/CV assay
Roche (RHHBY) announced that it has received U.S. FDA 510(k) clearance for its cobas BV/CV assay. This molecular diagnostic test provides results for both Bacterial vaginosis and Candida vaginitis fro...
Roche receives FDA clearance for the cobas® BV/CV assay, enabling fast and highly accurate vaginitis diagnosis
The new PCR test uses clinician-collected or clinician-instructed, self-collected vaginal swab specimens to simultaneously detect organisms associated with Bacterial vaginosis (BV) and Candida vaginit...
Roche Announces Positive CHMP Recommendation For Susvimo
(RTTNews) - Roche (RO.SW, ROG.SW) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of Susvimo 100 mg/mL for the treatment of n...
CHMP recommends EU approval of Roche's Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)
Basel, 24 July 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Susv...